Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-02-27
2007-02-27
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S343000
Reexamination Certificate
active
11375125
ABSTRACT:
The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I)or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
REFERENCES:
patent: 3299078 (1967-01-01), Pachter
patent: 3813392 (1974-05-01), Sellstedt et al.
patent: 3891643 (1975-06-01), Sellstedt et al.
patent: 3892746 (1975-07-01), Sellstedt et al.
patent: 3914421 (1975-10-01), Rajagopalan
patent: 4013652 (1977-03-01), Rajagopalan
patent: 4088647 (1978-05-01), Glushkov et al.
patent: 4115577 (1978-09-01), Rajagopalan
patent: 4183936 (1980-01-01), Rajagopalan
patent: 4219550 (1980-08-01), Rajagopalan
patent: 4238607 (1980-12-01), Rajagopalan
patent: 4997831 (1991-03-01), Bays et al.
patent: 5100884 (1992-03-01), Hamminga et al.
patent: 5223625 (1993-06-01), Van Wijngaarden et al.
patent: 5328905 (1994-07-01), Hamminga et al.
patent: 5512575 (1996-04-01), Jacobs et al.
patent: 5654139 (1997-08-01), Lappalainen et al.
patent: 5902815 (1999-05-01), Olney et al.
patent: 5908830 (1999-06-01), Smith et al.
patent: 6107324 (2000-08-01), Behan et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6407092 (2002-06-01), Hester et al.
patent: 200043637 (2000-11-01), None
patent: 2011107 (1991-08-01), None
patent: 0725068 (1996-08-01), None
patent: 2213283 (1974-02-01), None
patent: 0064899 (2000-11-01), None
Bickerdike, M.J., et al., “5-HT2C receptor modulation and the treatment of obesity”. Diabetes, Obesity and Metabolism 1: 207-214 (1999).
Tecott, L.H., et al., “Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors”, Nature, 374:542-546 (1995).
Cryan, J.F., et al., “Antidepressant-like behavioral effects mediated by 5-hydroxtryptamine2C receptors”. J. Pharmacol. Exper. Ther., 295: 1120-1126 (2000).
Millan, M.J. et al., “5-HT2C receptors mediate penile erection in rats: actions of novel and selective agonists and antagonists”, Eur. J. Pharmacol., 325:9-12 (1997).
Martin, J.R. et al., “5-HT2C receptor agonists: Pharmacological characteristics and therapeutic potential”, J. Pharmacol. Exper. Ther., 286: 913-924 (1998).
Meltzer, H.Y., “The role of serotonin in antipsychotic drug action”, Neuropsychopharmacology 21(2):1065-1155 (1999).
Curzon et al., “Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability”, TiPS, vol. 18, pp. 21-25 (1997).
Mora et al., “Role of 5-HT2A and 5-HT2C Receptor subtypes in the Two Types of Fear Generated by the Elevated T-Maze”, Pharma. Biochem. & Behavior, vol. 58, No. 4, pp. 1051-1057 (1997).
Jenck et al., “Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats”, European Neuropsychopharmacology, vol. 8., pp. 161-168 (1998).
Leysen, “Selective 5-HT2C agonists as potential antidepressants”, Drugs, vol. 2, No. 2, pp. 109-120, (1999).
Jenck et al., “The role of 5-HT2C receptors in affective disorders”, Exp. Opin. Invest. Drugs, vol. 7, No. 10, pp. 1587-1599 (1998).
Kennett, “5-HT drugs and eating disorders”, I Drugs, vol. 1, No. 4, pp. 456-470 (1998).
Brewerton, “Induction of migrainelike headaches by the serotonin agonist m-chlorophenylpiperazine”, Clin. Pharmacol. Ther., pp. 605-609 (1988).
Kahn et al., “m-chlorophenylpiperazine as a probe of serotonin function”, Biol. Psychiatry, vol. 30, pp. 1139-1166 (1991).
Gibson et al., “Evidence that mCPP-induced Anxiety in the Plus-maze is mediated by Postsynaptic 5-HT2c receptors but not by sympathomimetic effects”, Neuropharmacology, vol. 33, No. 3,4, pp. 457-465 (1994).
Calvello Emilie J.
Chen Wenting
Deng Wei
Haydar Simon
Lee Taekyu
Bristol-Myers Squibb Pharma Company
Duncan, Jr. Sammy G.
Kifle Bruck
LandOfFree
Substituted heterocycle fused γ-carbolines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted heterocycle fused γ-carbolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heterocycle fused γ-carbolines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3810504